Regeneron Pharmaceuticals Inc Total Assets
Regeneron Pharmaceuticals Inc total assets. Based on the latest financial reports, Regeneron Pharmaceuticals Inc (REGN) holds total assets worth $41.73 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how efficiently does Regeneron Pharmaceuticals Inc generate cash for how efficiently the company converts equity into cash flow.
Total Assets of Regeneron Pharmaceuticals Inc (1990–2025)
Total assets of Regeneron Pharmaceuticals Inc from 1990 to 2025. This chart illustrates how Regeneron Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See Regeneron Pharmaceuticals Inc (REGN) stock price for real-time trading data and today's change.
Regeneron Pharmaceuticals Inc - Asset Composition Analysis
Regeneron Pharmaceuticals Inc Total Assets Breakdown (December 2025)
Regeneron Pharmaceuticals Inc total assets breakdown as of December 2025. Regeneron Pharmaceuticals Inc's total assets of $41.73 Billion consist of 44.4% current assets and 55.6% non-current assets. Explore Regeneron Pharmaceuticals Inc (REGN) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.7% |
| Accounts Receivable | $5.74 Billion | 14.2% |
| Inventory | $3.20 Billion | 7.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.26 Billion | 3.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1990–2025)
This chart illustrates how Regeneron Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Regeneron Pharmaceuticals Inc's current assets represent 44.4% of total assets in 2025, a decrease from 88.2% in 1990.
- Cash Position: Cash and equivalents constituted 7.7% of total assets in 2025, down from 85.8% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 1.0% in 1990.
- Asset Diversification: The largest asset category is accounts receivable at 14.2% of total assets.
Regeneron Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Regeneron Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
|
USA | $488.54 Million |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
GH Research PLC
NASDAQ:GHRS
|
USA | $372.35 Million |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $575.89 Million |
Regeneron Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.34 | 4.60 | 3.71 |
| Quick Ratio | 2.78 | 3.72 | 3.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $12.92 Billion | $13.19 Billion | $10.06 Billion |
Regeneron Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Regeneron Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.60 |
| Latest Market Cap to Assets Ratio | 1.88 |
| Asset Growth Rate (YoY) | 7.4% |
| Total Assets | $40.56 Billion |
| Market Capitalization | $76.14 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Regeneron Pharmaceuticals Inc's assets above their book value (1.88x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Regeneron Pharmaceuticals Inc's assets grew by 7.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Regeneron Pharmaceuticals Inc (1990–2025)
The table below shows the annual total assets of Regeneron Pharmaceuticals Inc from 1990 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $40.56 Billion | +7.41% |
| 2024-12-31 | $37.76 Billion | +14.15% |
| 2023-12-31 | $33.08 Billion | +13.23% |
| 2022-12-31 | $29.21 Billion | +14.86% |
| 2021-12-31 | $25.43 Billion | +48.19% |
| 2020-12-31 | $17.16 Billion | +15.93% |
| 2019-12-31 | $14.81 Billion | +26.17% |
| 2018-12-31 | $11.73 Billion | +33.89% |
| 2017-12-31 | $8.76 Billion | +25.68% |
| 2016-12-31 | $6.97 Billion | +24.32% |
| 2015-12-31 | $5.61 Billion | +44.87% |
| 2014-12-31 | $3.87 Billion | +31.20% |
| 2013-12-31 | $2.95 Billion | +41.84% |
| 2012-12-31 | $2.08 Billion | +57.19% |
| 2011-12-31 | $1.32 Billion | +21.49% |
| 2010-12-31 | $1.09 Billion | +46.98% |
| 2009-12-31 | $741.20 Million | +10.62% |
| 2008-12-31 | $670.04 Million | -28.43% |
| 2007-12-31 | $936.26 Million | +60.02% |
| 2006-12-31 | $585.09 Million | +38.16% |
| 2005-12-31 | $423.50 Million | -10.49% |
| 2004-12-31 | $473.11 Million | -1.34% |
| 2003-12-31 | $479.56 Million | +22.47% |
| 2002-12-31 | $391.57 Million | -20.96% |
| 2001-12-31 | $495.40 Million | +137.86% |
| 2000-12-31 | $208.27 Million | +52.02% |
| 1999-12-31 | $137.00 Million | -12.68% |
| 1998-12-31 | $156.90 Million | -6.83% |
| 1997-12-31 | $168.40 Million | +22.38% |
| 1996-12-31 | $137.60 Million | +46.70% |
| 1995-12-31 | $93.80 Million | -0.42% |
| 1994-12-31 | $94.20 Million | -19.90% |
| 1993-12-31 | $117.60 Million | +20.12% |
| 1992-12-31 | $97.90 Million | -14.12% |
| 1991-12-31 | $114.00 Million | +348.82% |
| 1990-12-31 | $25.40 Million | -- |
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degenera… Read more